Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update

Abstract

Juvenile dermatomyositis is the most common type of juvenile idiopathic inflammatory myopathy mainly affecting the skin and proximal muscles. We have published the Japanese version of ‘Clinical practice guidance for juvenile dermatomyositis (JDM) 2018 ‘consisting of a review of articles in the field and evidence-informed consensus-based experts’ opinion on the treatment strategy in collaboration with The Pediatric Rheumatology Association of Japan and The Japan College of Rheumatology under the financial support by ‘Research on rare and intractable diseases, Health and Labor Sciences Research Grants’. This article is a digest version of the Japanese guidance.

Keywords:

• Diagnosis
• pathophysiology
• management
• interstitial lung disease
• myositis-specific autoantibodies

View correction statement:

Correction

Conflict of interest

Masaaki Mori: Tokyo Medical and Dental University (TMDU) received unrestricted research grants for Department of Lifetime Clinical Immunology from AbbVie GK, Ayumi Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., CSL Behring K. K., Japan Blood Products Organization, Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Towa Pharmaceutical Co., Ltd., UCB Japan Co. Ltd., with TMDU paid the salary of Masaaki Mori. All other authors have declared no conflicts of interest.

Additional information

Funding

Research on rare and intractable diseases, Health and Labor Sciences Research Grants for ‘Study about the standardization of diagnostic criteria and disease severity classification and the development of evidence-based treatment guidelines for pediatric rheumatic diseases such as mainly juvenile idiopathic arthritis’ (H27-nanchitou(nan)-ippan-029).